Cancer Family
Neck Neoplasm
CI-CAN-00000283Explore in graph →
Non-malignant634 active trials11 approved drugs67 evidence items
- NCIt
- C3260
Loading cancer entity…
Cancer Family
CI-CAN-00000283Explore in graph →
Clinical trials
2,377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05819593 | Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | Apr 19, 2023 | clinicaltrials |
| NCT05229315 | PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma | unknown | Phase 2 | 45 | XIANG YANQUNOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05278364 | Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 184 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05796960 | European Multicenter Study on Surgical Management of Advanced Thyroid Cancer(ATCEU) | unknown | — | 3,917 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT03905369 | Focus on Values to Stimulate Shared Decisions | unknown | N/A | 128 | Radboud University Medical CenterOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT03418909 | Functional Outcome After Treatment for Oropharyngeal Squamous Cell Carcinoma | unknown | — | 44 | Rigshospitalet, DenmarkOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT05790200 | Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma | unknown | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03700476 | Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma(CONTINUUM) | unknown | Phase 3 | 425 | Sun Yat-sen UniversityOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT05097209 | Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 200 | Wei JiangOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT05211427 | Bitter Taste Receptors in Oropharynx Cancer | unknown | N/A | 20 | Thomas HummelOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT05758025 | A New Surgical Strategy to Protect the Inferior Parathyroid | unknown | N/A | 506 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 7, 2023 | clinicaltrials |
| NCT04870905 | Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 100 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT00941538 | Cluster Randomized Controlled Screening Trial for NPC(CRCSTNPC) | unknown | N/A | 87,600 | Sun Yat-sen UniversityOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05395429 | Clinical Evaluation of Genetron TERT/BRAF PCR Kit in Thyroid Cancer Patients | unknown | — | 1,000 | Genetron HealthINDUSTRY | 1 | Feb 23, 2023 | clinicaltrials |
| NCT05724355 | CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC | unknown | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT04359199 | QUantitative Assessment of Swallowing After Radiation (QUASAR)(QUASAR) | unknown | — | 42 | Loren Mell, MDOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT05549466 | Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC | unknown | Phase 2 | 84 | Sun Yat-sen UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT04405622 | Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. | unknown | Phase 2 | 21 | Sun Yat-sen UniversityOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05568641 | Vitamin-D Receptor in Laryngeal Squamous Cell Carcinoma | unknown | — | 50 | Sohag UniversityOTHER | 0 | Jan 18, 2023 | clinicaltrials |
| NCT05682703 | A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Nasopharyngeal Carcinoma. | unknown | — | 2,000 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT05679856 | Vocal Cord vs Whole Laryngeal Radiotherapy for T1aN0 Glottic Cancer(VC-Larynx) | unknown | N/A | 50 | National Cancer Institute, EgyptOTHER | 1 | Jan 11, 2023 | clinicaltrials |
| NCT05659186 | PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer | unknown | Phase 2 | 20 | West China HospitalOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT05654077 | EBV CAR-T Cells for Nasopharyngeal Carcinoma | unknown | Early Phase 1 | 24 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Dec 19, 2022 | clinicaltrials |
| NCT05616468 | BGT007 Cell Treatment of Nasopharyngeal Carcinoma | unknown | Early Phase 1 | 23 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT04650919 | Aortic Laryngeal Rehabilitation Graft(GRAAL) | unknown | N/A | 4 | University Hospital, Strasbourg, FranceOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT05627310 | Development and Validation of a Deep Learning System for Nasopharyngeal Carcinoma Using Endoscopic Images | unknown | — | 50,000 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT01855451 | Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma(HPVOropharynx) | unknown | Phase 3 | 189 | Trans Tasman Radiation Oncology GroupOTHER | 2 | Nov 18, 2022 | clinicaltrials |
| NCT05415098 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | unknown | Phase 1 | 90 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Nov 16, 2022 | clinicaltrials |
| NCT05532384 | Effect of Early Postoperative Drinking Water on Postoperative Recovery Quality of Patients With Thyroid Surgery | unknown | N/A | 94 | Peking Union Medical College HospitalOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT03837808 | Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma | unknown | Phase 3 | 384 | Sun Yat-sen UniversityOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT03432299 | Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma(RFAforPTMC) | unknown | N/A | 100 | Seoul National University HospitalOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT05595265 | Expression of Programmed Death Ligand-1 (PD-L1) in Nasopharyngeal and Hyypopharyngeal Carcinoma | unknown | — | 50 | Sohag UniversityOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT05468554 | Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid Cancer(METHYR) | unknown | Phase 3 | 160 | Medical University of BialystokOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT02063399 | Prospective Nasopharyngeal Carcinoma Screening Using Plasma Epstein-Barr Virus DNA Analysis | unknown | — | 20,302 | Chinese University of Hong KongOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT05556499 | The Bone-parathyroid Crosstalk in Primary Hyperparathyroidism(PARABONE) | unknown | — | 100 | I.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT05551767 | Induction Immunochemotherapy in Stage III-IVa Head and Neck Cancer | unknown | Phase 2 | 120 | City Clinical Oncology Hospital No 1OTHER_GOV | 1 | Sep 23, 2022 | clinicaltrials |
| NCT05547971 | Development of Intelligent Model for Radioactive Brain Damage of Nasopharyngeal Carcinoma Based on Radio-metabolomics | unknown | — | 800 | Xiangya Hospital of Central South UniversityOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT05519956 | Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines | unknown | Phase 3 | 398 | Fujian Cancer HospitalOTHER_GOV | 0 | Sep 19, 2022 | clinicaltrials |
| NCT05510609 | Three-dimensional Ultrasonography Thyroid Volume Measurement. | unknown | N/A | 17 | Rigshospitalet, DenmarkOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT04898374 | Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma | unknown | Phase 3 | 120 | Kuwait Cancer Control CenterOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT05503914 | Low-dose Radiotherapy and Neoadjuvant Chemotherapy Sequential Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma | unknown | N/A | 80 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT03830242 | Diagnostic Significance of FDG PET/CT Dynamic Imaging in Detecting Metastatic Lymph Nodes With Papillary Thyroid Cancer. | unknown | N/A | 50 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT05448885 | Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma | unknown | Phase 2 | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT04398056 | Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 22 | Sun Yat-sen UniversityOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05037357 | Verification of Harmonization of Plasma Epstein-Barr Virus DNA Measurements | unknown | — | 370 | Sun Yat-sen UniversityOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05446441 | Endoscopic Thyroidectomy Versus Open Thyroidectomy for Papillary Thyroid Carcinoma | unknown | N/A | 634 | Zhejiang Provincial People's HospitalOTHER | 0 | Jul 6, 2022 | clinicaltrials |
| NCT03707509 | Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 3 | 263 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05432219 | A Transoral Retropterygoid Approach to Resect Recurrent Nasopharyngeal Carcinoma | unknown | N/A | 20 | Eye & ENT Hospital of Fudan UniversityOTHER | 0 | Jun 27, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Apr 19, 2023source: clinicaltrials